Meeting
2014 ASCO Annual Meeting
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
Authors
Matthew R. Zibelman
Fox Chase Cancer Center, Philadelphia, PA
Matthew R. Zibelman , Yu-Ning Wong , Lois Malizzia , Alycia Corrigan , Anthony J. Olszanski , Crystal Shereen Denlinger , Susan K. Roethke , Colleen H. Tetzlaff , Gary R. Hudes , Elizabeth R. Plimack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01169532
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4568)
DOI
10.1200/jco.2014.32.15_suppl.4568
Abstract #
4568
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.
First Author: Elizabeth R. Plimack
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2015 ASCO Annual Meeting
Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
First Author: Haeseong Park